Ketoprofen lysine salt (Artrosilene", injectable solution) is a non-steroidal anti-inflammatory agent frequently administered by slow intravenous infusion with portable elastomeric infusion systems in association regimen with other analgesic drugs. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt (Artrosilene", injectable solution) and other injectable drugs frequently used in association, such as tramadol hydrochloride, keterolac tromethamine and morphine hydrochloride, into the Infusor LV5, Baxter elastomeric infusion system. Physicochemical properties of drug mixture, including colour, clarity, pH and drug content were observed or measured by a reversed-phase HPLC method with UV detection, before and after (up to 7 days) mixing at room temperature and under light protection. The results obtained demonstrated the physicochemical compatibility of ketoprofen lysine salt (Artrosilene", injectable solution) with all drug formulations at every tested mixing ratios into Baxer Infusor LV5 infusion devices.
Ketoprofen
lysine salt, or (RS)-2-(3benzoylphenyl) propionic acid (DL)-lysine salt ( Fig. I) , is an arylpropionic non-steroidal antiinflammatory drug, prescribed for the treatment of traumatic, orthopaedic and rheumatic disorders because of its anti-inflammatory and analgesic properties (1) . Since it is very often co-administered with other drugs, by intravenous infusion the possible interactions between the drugs used should be carefully evaluated. The combined therapy requires the knowledge of the mixture's physicochemical compatibility, which can be achieved by investigating the main physicochemical parameters, such as appearance (physical state and colour), pH and content of all active drugs of the mixture. Two mixed pharmaceutical products can be considered compatible when no significant variation of physicochemical characteristics of the mixture occurs over the time required for administration. In fact, when two or more substances are mixed together, physical and/or chemical changes can occur (2) , leading to a variation of therapeutic properties and undesirable side effects. Generally, drugs in an extemporary mixture are considered chemically incompatible when the content decrease of any active drug is more than 10% of their nominal value (3) (4) (5) (6) (7) (8) (9) .
The chemical interactions between drugs could result in molecular changes or rearrangements to different chemical entities of the active compounds. The term physical incompatibility or, more accurately, visual incompatibility is used when the incompatibility results in visible changes such as precipitation, turbidity or haziness, changes in colour or viscosity, effervescence, or formation of immiscible liquid layers (l0-12). Drugs may undergo a variety of chemical degradation pathways, such as hydrolysis, oxidation or reduction reactions, photo degradation, racemization or epimerization. Solution pH and temperature are the most important factors that influence the rate of drugs decomposition in drug delivery systems. Drug concentration, light exposure and solution ion strength are also important factors (13-,14) . Most chemical incompatibilities are not visibly observable, therefore a useful technique to assure the drugs' pharmaceutical integrity is to perform the quantitative determination of the drugss before and after mixing by means of very selective and sensitive analytical methods such as chromatography.
In this study an experimental protocol was designed to investigate the physicochemical compatibility of the associations at various mixing ratios between Artrosilene" injectable solution 160 mg/2mL (Dompe S.p.A., Italy), a marketed injectable formulation, and the following pharmaceutical products: Contramal" 100 mg/2mL injectable solution (Prodotti Formenti, s.r.l., Italy), TORA-DOL® 30 mg injectable solution (Recordati S.p.A., Italy) and Morphine hydrochloride Monico 20 mg/lmL injectable solution (Monico S.p.A., Italy). The mixtures were prepared in saline and maintained at room temperature, under light protection, into Baxter Infusor LV 5 elastomeric infusion devices and into amber glass vials as a comparison. The following physicochemical parameters were evaluated immediately after mixing and after 12 hours, 1,2, and 7 days: colour, clarity, pH and drugs content.
MATERIALS AND METHODS

Chemicals
Acetonitrile (HPLC grade) and sodium phosphate dibasic (AnalaR grade) were supplied by Fluka Chemika-BioChemika (Buchs, Switzerland). Phosphoric acid and sodium chloride were obtained from Carlo Erba Reagenti (Milan, Italy). Water (HPLC grade) was obtained by passage through the ELIX 3 and Milli-Q Academic water purification system (Millipore, Bedford, MA, USA). Other chemicals and reagents were of analytical grade. The compatibility study was conducted using the Baxter Portable Elastomeric Infusion System Model. INFUSOR LV 5 compared to amber glass vials.
The following marketed products were used for preparation of the mixtures:
Artrosilene" injectable solution 160mg/2mL injectable solution: ketoprofen lysine salt 160 mg, citric acid, sodium hydroxide, water for injection; 2 mL (Dompe S.p.A., Italy).
Contramal" 100mg/2mL injectable solution: tramadol hydrochloride 100 mg, sodium acetate 8.3 mg, water for injection; 2mL (Prodotti Formenti s.r.l., Italy).
TORA-DOL~' 30mg injectable solution: ketorolac tromethamine 30mg, alcohollOOmg, sodium chloride 4.35 mg, water for injection; 1 mL (Recordati S.p.A., Italy).
Morphine hydrochloride Monico 20 mg/lmL injectable solution: morphine hydrochloride trihydrate 20 mg, water for injection; 1 mL (Monico S.p.A., Italy).
Sodium chloride 0.9% physiological solution (Bieffe Medital S.p.A. Italy).
Chromatographic system and conditions
HPLC analysis was carried out using a chromatographic system composed of the following: a Model 2695 sample injector and pump system, a Model 2487 UV-Vis detector (Waters, Milford, MA, USA). Chromatographic data management was automated using a Empower software (Waters, Milford, MA, USA). Separation was achieved by on an analytical 250 x 4.6 rom i.d. reversed-phase Luna CIS (5 urn particle size) column (Phenomenex, CA, USA). The assay was performed at ambient temperature. The mobile phase consisted of a mixture of acetonitrile and 0.05 M Na 2HP04 (pH=7 with H 3P04 ) . The aqueous phosphate buffer, prior to use, was filtered through a WCN 0.45 urn, filter while acetonitrile through WTP 0.5 urn filter (Whatmann, Ltd, Maidstone, UK). The mobile phase was prepared daily, degassed using an in-line degasser (Waters, Milford, MA), and delivered at a flow rate of 1.5 mL/min. 10 ul, aliquots were injected for chemical analysis. Column eleuate was monitored at 254 nm.
Sample preparation
Before submitting for HPLC analysis, samples were appropriately diluted with Milli-Q grade water. Sample dilution factors before analysis are reported in Table II. The mixed drugs mixed, the mixing volumes and ratios and the final infusion volumes are detailed in Table I . All mixtures were prepared both into amber glass vials and elastomeric infusion systems. The dilution solvent of the drug mixtures was a sterile and pyrogen free 0.9 % sodium All mixtures obtained mixtures contained into both the elastomeric infusion system and the glass vials were protected from light by an aluminium foil,due to the well known photoinstability of ketoprofen. All mixtures were maintained at room temperature for the entire stability period.
Colour and clarity of the mixtures were visually evaluated against a white background. pH was measured by a Model MP 220 pHmeter (Mettler, Toledo). These parameters were assessed before mixing, for each single formulation, immediately after mixing (time zero) and after 12 hours, I, 2 and 7 days from mixing.
RESULTS
The characteristics of the preparations selected for the compatibility study with Artrosilene" injectable are reported in Tables III to V.Table III shows colour, clarity and pH of the each single pharmaceutical products selected for the compatibility study with Artrosilene" injectable solution. The single pharmaceutical products showed pH values ranging from 4.5 to 7.3; Artrosilene" formulation pH was 7.2. Table IV shows Artrosilene" + Contramal" Artrosilene® + Contramal" 6.9 Artrosilene'" + Contramal" 6.9 Artrosilene" + Contramal I  I  I  I  I  I  I  I  I tested. The colour, clarity and pH of all mentioned mixtures did not change significantly over 7 days after mixing.
In Figure 2 the pH of each single formulation is compared with the pH obtained after mixing with Artrosilene" injectable solution. It is noteworthy that the pH values ofthe obtained mixtures are near to the physiological value, even the mixture with morphine hydrochloride, thanks to the buffer system contained in Artrosilene" injectable solution. The buffered Artrosilene" injectable formulation ensures the maintenance of proper values of pH, more suitable for a safer intravenous administration.
The results of HPLC analysis of the mixtures at zero (immediately after mixing), 0.5, 1,2 and 7 days after mixing are reported in Table V. HPLC analysis confirmed the chemical compatibility between the formulations. In all mixtures the content of ketoprofen lysine salt and associated active drug did not significantly change over the testing period. The obtained results shows that the content variation of content of all the active drugs remained well within 10% of their nominal values. Furthermore, there was no evidence of interaction/degradation products between the mixed drugs. An isocratic reversed-phase method has been described for the physicochemical compatibility of Artrosilene" injectable solution and other drug formulations. The retention times for morphine, ketorolac, and ketoprofen were 2.4, 4.4, and 7.2 min, ( Fig. 3-5 ) respectively, using a mobile phase described in the figure captions, while for the mixture tramadol hydrochloride -ketoprofen lysine salt mixture the retention times were 10.0 and 15.0 min respectively, where the mobile phase was a mixture of phosphate buffer -acetonitrile (80:20, v/v). No interfering substance was observed in the chromatograms. Under the experimental conditions used, a good separation ofketoprofen from tramadol, ketorolac and morphine were obtained. The proposed LC method requires only dilution samples with water, and injection of an aliquot into suitable chromatograph.
DISCUSSION
The possibility of combined therapy of Artrosilene" injectable solution with various drugs (Contramal" 100 mg/2mL injectable solution, TORA-DOU 30mg injectable solution, Morphine hydrochloride Monico 20 mg/lmL injectable solution) by the intravenous route using portable elastomeric infusion devices requires the evaluation of the physicochemical compatibility of the extemporary mixture to be performed. On the basis of existing literatures (3) (4) (5) (6) (7) (8) an experimental protocol was designed to investigate the compatibility between Artrosilene" injectable and other drug formulations.
The observations and the measurements performed (colour, clarity, pH and content of active drugs) demonstrated the physicochemical compatibility of the extemporary mixtures of Artrosilene" injectable solution with some analgesic drugs into Baxter Infusor LV 5 infusion devices.
The availability of physicochemical compatibility data related to parenteral administration of analgesics can facilitate prompt preparation and dispensing of medications to the patient. This allows a more efficient control of pain and time-saving and optimization of human resources involved in patient care.
